• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

pT1 期卵巢透明细胞癌中不规则巨核细胞存在的临床及预后价值。

Clinical and prognostic value of the presence of irregular giant nuclear cells in pT1 ovarian clear cell carcinoma.

机构信息

Department of Obstetrics and Gynecology, Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan.

出版信息

Pathol Oncol Res. 2011 Sep;17(3):605-11. doi: 10.1007/s12253-010-9356-5. Epub 2011 Jan 28.

DOI:10.1007/s12253-010-9356-5
PMID:21274673
Abstract

In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for >10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7-124 and adjusted hazard ratio = 25, 95% confidence interval =  2.9-768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%, P = 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC.

摘要

在卵巢上皮性癌的早期阶段,组织病理学分级很重要。然而,卵巢透明细胞癌(OCCC)的分级仍存在争议。我们旨在通过一种简单的方法在临床实践中识别不规则巨核细胞(IGNC),并评估 pT1 OCCC 中 IGNC 的预后价值。我们回顾性评估了在日本千叶市筑波大学济科医院接受初次手术的 87 例 pT1 OCCC 患者。对苏木精和伊红染色的石蜡包埋组织切片(PTS)进行了回顾。巨核细胞(GNC)定义为细胞核长度超过中位数细胞核长度两倍的细胞。具有不规则核轮廓的 GNC 被定义为 IGNC。存在一个或多个 GNC 且 IGNC 占 GNC 总数的>10%的病例被归类为 IGNC 阳性。我们还试图在触印细胞学涂片(TICS)上识别 IGNC。在 87 例病例中,68 例为 IGNC 阴性,19 例为 IGNC 阳性。总患者的 5 年无病生存率和总生存率分别为 88.9%和 90.3%,IGNC 阴性组为 98.3%和 100%,IGNC 阳性组为 59.7%和 62.0%。IGNC 阳性组的这些生存率明显低于 IGNC 阴性组(调整后的危险比=14,95%置信区间=2.7-124 和调整后的危险比=25,95%置信区间=2.9-768)。其他因素未发现预后差异。28 例可获得的 TICS 上的 IGNC 识别预测了 PTS 上的 IGNC 识别(敏感性=50.0%,特异性=100%,P=0.007)。存在 IGNC 对 pT1 OCCC 具有临床和预后价值。

相似文献

1
Clinical and prognostic value of the presence of irregular giant nuclear cells in pT1 ovarian clear cell carcinoma.pT1 期卵巢透明细胞癌中不规则巨核细胞存在的临床及预后价值。
Pathol Oncol Res. 2011 Sep;17(3):605-11. doi: 10.1007/s12253-010-9356-5. Epub 2011 Jan 28.
2
Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.Ⅰ期卵巢透明细胞癌中白细胞介素-6 表达的预后影响。
Gynecol Oncol. 2017 Sep;146(3):609-614. doi: 10.1016/j.ygyno.2017.06.027. Epub 2017 Jun 30.
3
Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma.早期卵巢透明细胞癌行全面淋巴结切除术的治疗意义。
J Gynecol Oncol. 2018 Mar;29(2):e19. doi: 10.3802/jgo.2018.29.e19. Epub 2017 Dec 11.
4
Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?子宫内膜异位症的存在与纯卵巢透明细胞癌的生存获益相关吗?
Arch Gynecol Obstet. 2018 Apr;297(4):1005-1013. doi: 10.1007/s00404-018-4651-6. Epub 2018 Jan 30.
5
Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.与其他上皮性卵巢癌相比,卵巢透明细胞癌接受紫杉醇和卡铂治疗后的临床结局。
Asian Pac J Cancer Prev. 2009;10(6):1041-5.
6
The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.纯卵巢透明细胞癌、混合型和高级别浆液性腺癌病例的临床特征及转归
Arch Gynecol Obstet. 2015 Oct;292(4):923-9. doi: 10.1007/s00404-015-3699-9. Epub 2015 Apr 9.
7
Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma.TNM分期为T1期的卵巢透明细胞腺癌患者中细胞核形态测量的预后价值。
Br J Cancer. 1999 Apr;79(11-12):1736-41. doi: 10.1038/sj.bjc.6690276.
8
Comorbid thrombosis as an adverse prognostic factor in patients with ovarian clear cell carcinoma regardless of staging.合并血栓形成作为卵巢透明细胞癌患者的不良预后因素,与分期无关。
Int J Clin Oncol. 2024 Sep;29(9):1347-1353. doi: 10.1007/s10147-024-02561-9. Epub 2024 Jul 22.
9
Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.浆液性和透明细胞组织学类型的原发性卵巢腺癌的人口统计学、临床及预后因素——一项比较研究
Int J Gynecol Cancer. 2016 Jan;26(1):82-90. doi: 10.1097/IGC.0000000000000585.
10
Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.子宫内膜异位症并不会改善卵巢透明细胞癌的预后:单中心回顾性研究。
J Ovarian Res. 2018 Jun 26;11(1):53. doi: 10.1186/s13048-018-0425-9.

本文引用的文献

1
Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.与其他上皮性卵巢癌相比,卵巢透明细胞癌接受紫杉醇和卡铂治疗后的临床结局。
Asian Pac J Cancer Prev. 2009;10(6):1041-5.
2
Intraoperative assessment of clear cell carcinoma of the ovary.卵巢透明细胞癌的术中评估
Int J Gynecol Pathol. 2008 Oct;27(4):475-82. doi: 10.1097/PGP.0b013e31816b5cff.
3
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
与其他上皮细胞类型相比,透明细胞卵巢癌的预后是否更差?一项对1411例透明细胞卵巢癌的研究。
Gynecol Oncol. 2008 Jun;109(3):370-6. doi: 10.1016/j.ygyno.2008.02.006. Epub 2008 Apr 18.
4
Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients?对于卵巢透明细胞癌患者,腹膜后淋巴结切除术与生存获益之间是否存在关联?
Ann Oncol. 2008 Jul;19(7):1284-1287. doi: 10.1093/annonc/mdn059. Epub 2008 Mar 19.
5
Grading of ovarian cancer: a histotype-specific approach.卵巢癌分级:一种组织学类型特异性方法。
Int J Gynecol Pathol. 2008 Apr;27(2):175-81. doi: 10.1097/PGP.0b013e31816085e0.
6
Management of retroperitoneal lymph nodes in the treatment of ovarian cancer.卵巢癌治疗中腹膜后淋巴结的管理
Int J Clin Oncol. 2007 Jun;12(3):181-6. doi: 10.1007/s10147-007-0672-z. Epub 2007 Jun 27.
7
Prognostic ability of simplified nuclear grading of renal cell carcinoma.肾细胞癌简化核分级的预后能力
Cancer. 2007 Mar 1;109(5):868-74. doi: 10.1002/cncr.22463.
8
Grading systems in renal cell carcinoma.肾细胞癌的分级系统
J Urol. 2007 Feb;177(2):430-6. doi: 10.1016/j.juro.2006.09.034.
9
Association of lymphadenectomy and survival in stage I ovarian cancer patients.Ⅰ期卵巢癌患者淋巴结清扫与生存情况的相关性
Obstet Gynecol. 2007 Jan;109(1):12-9. doi: 10.1097/01.AOG.0000249610.95885.ef.
10
Intraoperative cytology of clear cell carcinoma of the ovary.卵巢透明细胞癌的术中细胞学检查
Cytopathology. 2006 Dec;17(6):390-5. doi: 10.1111/j.1365-2303.2006.00373.x.